Historical source coverage
124 selected records with a cited source date in 2024. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Regulatory · Teriparatide
DailyMed lists Structured Product Labeling version 6 for the reviewed Teriparatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Tirzepatide
DailyMed lists Structured Product Labeling version 14 for the reviewed Tirzepatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Setmelanotide
PubMed lists PMID 39549717 in The lancet. Diabetes & endocrinology as Journal Article, with publication-date metadata of 2024-11-13 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Tesamorelin
DailyMed lists Structured Product Labeling version 7 for the reviewed Tesamorelin label family with a published date of 2024-12-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Liraglutide
The official Drugs@FDA dataset lists original submission 1 for ANDA 215503 with status AP dated 2024-12-23, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Vosoritide
DailyMed lists Structured Product Labeling version 15 for the reviewed Vosoritide label family with a published date of 2024-12-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Lixisenatide
PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide.
Source: ClinicalTrials.gov ↗
Literature metadata · Elamipretide
PubMed lists PMID 39669625 in Genetics in medicine open as Journal Article, with publication-date metadata of 2024-06-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Semaglutide
DailyMed lists Structured Product Labeling version 10 for the reviewed Semaglutide label family with a published date of 2024-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Glucagon
The official Drugs@FDA dataset lists original submission 1 for ANDA 204468 with status AP dated 2024-12-12, and names glucagon among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT01950403 at 2026-07-30T18:37:14.701Z. Its registry update date was 2024-12-09, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06629688 at 2026-07-30T18:37:14.696Z. Its registry update date was 2024-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02685397 at 2026-07-30T18:37:14.689Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT05912621 at 2026-07-30T18:37:14.695Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Regulatory · Lanreotide
DailyMed lists Structured Product Labeling version 2 for the reviewed Lanreotide label family with a published date of 2024-12-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04966741 at 2026-07-30T18:38:25.516Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03035032 at 2026-07-30T18:38:25.519Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT03965130 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory · Exenatide
DailyMed lists Structured Product Labeling version 11 for the reviewed Exenatide label family with a published date of 2024-11-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02366494 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Literature metadata · Setmelanotide
PubMed lists PMID 39526054 in TouchREVIEWS in endocrinology as Journal Article, Review, with publication-date metadata of 2024-02-09 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Liraglutide
The Federal Register published notice 2024-27048, attributed to FDA and its parent HHS department, on 2024-11-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
Source: Federal Register via GovInfo ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT04883346 at 2026-07-30T18:38:25.517Z. Its registry update date was 2024-11-20, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory · Exenatide
The official Drugs@FDA dataset lists original submission 1 for ANDA 206697 with status AP dated 2024-11-19, and names exenatide synthetic among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Leuprolide
DailyMed lists Structured Product Labeling version 6 for the reviewed Leuprolide label family with a published date of 2024-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Semaglutide
DailyMed lists Structured Product Labeling version 9 for the reviewed Semaglutide label family with a published date of 2024-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 54 for the reviewed Dulaglutide label family with a published date of 2024-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Lixisenatide
DailyMed lists Structured Product Labeling version 19 for the reviewed Lixisenatide label family with a published date of 2024-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Vosoritide
DailyMed lists Structured Product Labeling version 14 for the reviewed Vosoritide label family with a published date of 2024-11-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Bremelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04943068 at 2026-07-30T18:38:25.522Z. Its registry update date was 2024-11-13, and PeptideScanner's reviewed identity mapping was bremelanotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Dulaglutide
PubMed lists PMID 39126516 in Acta diabetologica as Journal Article, with publication-date metadata of 2024-08-10 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Tirzepatide
DailyMed lists Structured Product Labeling version 12 for the reviewed Tirzepatide label family with a published date of 2024-11-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Cagrilintide
PeptideScanner retained ClinicalTrials.gov record NCT05804162 at 2026-07-30T18:38:25.523Z. Its registry update date was 2024-11-01, and PeptideScanner's reviewed identity mapping was cagrilintide.
Source: ClinicalTrials.gov ↗
Literature metadata · Lixisenatide
PubMed lists PMID 38949062 in Biomacromolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-01 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · MOTS-c
PubMed lists PMID 39469962 in Ginekologia polska as Journal Article, with publication-date metadata of 2023 (year precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · CJC-1295
The Federal Register published notice 2024-24828, attributed to FDA and its parent HHS department, on 2024-10-25. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to CJC-1295.
Source: Federal Register via GovInfo ↗
Clinical trials · Mazdutide
PeptideScanner retained ClinicalTrials.gov record NCT06519656 at 2026-07-30T18:39:33.787Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was mazdutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT03471728 at 2026-07-30T18:39:33.779Z. Its registry update date was 2024-10-18, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Regulatory · Leuprolide
The official Drugs@FDA dataset lists original submission 1 for ANDA 217957 with status AP dated 2024-10-17, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Bremelanotide
PeptideScanner retained ClinicalTrials.gov record NCT05709444 at 2026-07-30T18:39:33.780Z. Its registry update date was 2024-10-17, and PeptideScanner's reviewed identity mapping was bremelanotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Vosoritide
PubMed lists PMID 39399714 in Translational pediatrics as Editorial, Comment, with publication-date metadata of 2024-09-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT05708859 at 2026-07-30T18:39:33.781Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Literature metadata · Ziconotide
PubMed lists PMID 39386004 in Journal of pharmaceutical analysis as Journal Article, with publication-date metadata of 2024-07-02 (day precision). PeptideScanner associated the retained record with the identity slug ziconotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · MOTS-c
PubMed lists PMID 29242099 in International journal of cardiology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2017-12-06 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04216589 at 2026-07-30T18:39:33.783Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory · Octreotide
The official Drugs@FDA dataset lists original submission 1 for NDA 213224 with status AP dated 2024-09-27, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Ipamorelin
The Federal Register published notice 2024-21241, attributed to FDA and its parent HHS department, on 2024-09-18. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List,” and PeptideScanner's exact reviewed identity mapping connects the document to Ipamorelin.
Source: Federal Register via GovInfo ↗
Regulatory · Elamipretide
The Federal Register published notice 2024-20062, attributed to FDA and its parent HHS department, on 2024-09-06. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.
Source: Federal Register via GovInfo ↗
Literature metadata · BPC-157
PubMed lists PMID 39204186 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2024-08-17 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03574597 at 2026-07-30T18:41:37.951Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT06099067 at 2026-07-30T18:41:37.931Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata · Ipamorelin
PubMed lists PMID 38996787 in Animal reproduction science as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug ipamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Exenatide + 1 more
The Federal Register published notice 2024-18898, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Glucagon.
Source: Federal Register via GovInfo ↗
Regulatory · Teriparatide
The Federal Register published notice 2024-18997, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide.
Source: Federal Register via GovInfo ↗
Regulatory · Pramlintide
DailyMed lists Structured Product Labeling version 18 for the reviewed Pramlintide label family with a published date of 2024-08-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · BPC-157
PubMed lists PMID 34829776 in Biomedicines as Journal Article, with publication-date metadata of 2021-10-27 (day precision). PeptideScanner associated the retained record with the identity slug bpc-157. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Afamelanotide
DailyMed lists Structured Product Labeling version 8 for the reviewed Afamelanotide label family with a published date of 2024-08-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03036800 at 2026-07-30T18:41:37.923Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory · Tirzepatide
DailyMed lists Structured Product Labeling version 8 for the reviewed Tirzepatide label family with a published date of 2024-08-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Glucagon
The Federal Register published notice 2024-17649, attributed to FDA and its parent HHS department, on 2024-08-08. Its official title is “Determination That DELATESTRYL (Testosterone Enanthate) Injection, 200 Milligrams/Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
Source: Federal Register via GovInfo ↗
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06541509 at 2026-07-30T18:41:37.930Z. Its registry update date was 2024-08-07, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Literature metadata · Elamipretide
PubMed lists PMID 32096613 in Journal of cachexia, sarcopenia and muscle as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Bremelanotide
PubMed lists PMID 32353679 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2020-03-27 (day precision). PeptideScanner associated the retained record with the identity slug bremelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Vosoritide
PubMed lists PMID 39062238 in Children (Basel, Switzerland) as Journal Article, with publication-date metadata of 2024-06-28 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 51 for the reviewed Dulaglutide label family with a published date of 2024-07-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02403284 at 2026-07-30T18:42:56.623Z. Its registry update date was 2024-07-22, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata · Retatrutide
PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Elamipretide
PubMed lists PMID 36840897 in GeroScience as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT06498063 at 2026-07-30T18:42:56.616Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Regulatory · Linaclotide
DailyMed lists Structured Product Labeling version 34 for the reviewed Linaclotide label family with a published date of 2024-07-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Plecanatide
PeptideScanner retained ClinicalTrials.gov record NCT05151328 at 2026-07-30T18:42:56.581Z. Its registry update date was 2024-07-11, and PeptideScanner's reviewed identity mapping was plecanatide.
Source: ClinicalTrials.gov ↗
Regulatory · Pramlintide
DailyMed lists Structured Product Labeling version 17 for the reviewed Pramlintide label family with a published date of 2024-07-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Teriparatide
DailyMed lists Structured Product Labeling version 5 for the reviewed Teriparatide label family with a published date of 2024-07-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT05849389 at 2026-07-30T18:43:56.187Z. Its registry update date was 2024-06-24, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Clinical trials · Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT04249232 at 2026-07-30T18:43:56.172Z. Its registry update date was 2024-06-14, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02927392 at 2026-07-30T18:43:56.185Z. Its registry update date was 2024-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT05766358 at 2026-07-30T18:43:56.186Z. Its registry update date was 2024-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01194271 at 2026-07-30T18:43:56.180Z. Its registry update date was 2024-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory · Teriparatide
The official Drugs@FDA dataset lists original submission 1 for NDA 218771 with status AP dated 2024-06-04, and names teriparatide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02157974 at 2026-07-30T18:43:56.184Z. Its registry update date was 2024-06-04, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Regulatory · Glucagon
The Federal Register published notice 2024-12065, attributed to FDA and its parent HHS department, on 2024-06-03. Its official title is “Pfizer, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
Source: Federal Register via GovInfo ↗
Literature metadata · Vosoritide
PubMed lists PMID 38813446 in EClinicalMedicine as Journal Article, with publication-date metadata of 2024-04-11 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03987451 at 2026-07-30T18:45:10.889Z. Its registry update date was 2024-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Literature metadata · Afamelanotide
PubMed lists PMID 38784937 in Postepy dermatologii i alergologii as Journal Article, Review, with publication-date metadata of 2024-04-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Lanreotide
DailyMed lists Structured Product Labeling version 1 for the reviewed Lanreotide label family with a published date of 2024-05-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Lixisenatide
PubMed lists PMID 28179743 in Hospital pharmacy as Journal Article, with publication-date metadata of 2017-01 (month precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Lanreotide
The official Drugs@FDA dataset lists original submission 1 for ANDA 217193 with status AP dated 2024-05-21, and names lanreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Liraglutide
The Federal Register published notice 2024-10896, attributed to FDA and its parent HHS department, on 2024-05-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
Source: Federal Register via GovInfo ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT04909333 at 2026-07-30T18:45:10.887Z. Its registry update date was 2024-05-08, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT05046132 at 2026-07-30T18:45:10.886Z. Its registry update date was 2024-05-03, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Regulatory · Octreotide
The official Drugs@FDA dataset lists original submission 1 for ANDA 217860 with status AP dated 2024-05-02, and names octreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Leuprolide
The Federal Register published notice 2024-08657, attributed to FDA and its parent HHS department, on 2024-04-23. Its official title is “PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
Source: Federal Register via GovInfo ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT04522622 at 2026-07-30T18:46:20.407Z. Its registry update date was 2024-04-23, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Elamipretide
PeptideScanner retained ClinicalTrials.gov record NCT03098797 at 2026-07-30T18:46:20.414Z. Its registry update date was 2024-04-16, and PeptideScanner's reviewed identity mapping was elamipretide.
Source: ClinicalTrials.gov ↗
Regulatory · Pramlintide
DailyMed lists Structured Product Labeling version 16 for the reviewed Pramlintide label family with a published date of 2024-04-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Vosoritide
DailyMed lists Structured Product Labeling version 12 for the reviewed Vosoritide label family with a published date of 2024-04-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Semaglutide
DailyMed lists Structured Product Labeling version 8 for the reviewed Semaglutide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Tirzepatide
DailyMed lists Structured Product Labeling version 5 for the reviewed Tirzepatide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Vosoritide
DailyMed lists Structured Product Labeling version 11 for the reviewed Vosoritide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Plecanatide
DailyMed lists Structured Product Labeling version 15 for the reviewed Plecanatide label family with a published date of 2024-04-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05813249 at 2026-07-30T18:46:20.405Z. Its registry update date was 2024-04-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Literature metadata · MOTS-c
PubMed lists PMID 38462167 in Neuroscience letters as Journal Article, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Abaloparatide
PubMed lists PMID 33638863 in Clinical drug investigation as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2021-02-27 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Elamipretide
PubMed lists PMID 32554501 in Proceedings of the National Academy of Sciences of the United States of America as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-06-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Linaclotide
PubMed lists PMID 29184433 in International journal of general medicine as Journal Article, Review, with publication-date metadata of 2017-10-31 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Semaglutide
DailyMed lists Structured Product Labeling version 7 for the reviewed Semaglutide label family with a published date of 2024-03-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT06303284 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Regulatory · Tesamorelin
DailyMed lists Structured Product Labeling version 6 for the reviewed Tesamorelin label family with a published date of 2024-03-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Elamipretide
PubMed lists PMID 29951944 in Cardiovascular drugs and therapy as Journal Article, with publication-date metadata of 2018-08 (month precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · TB-500
PeptideScanner retained PubMed bibliographic metadata for PMID 38382158 at 2026-07-30T18:48:13.580Z. PubMed recorded a metadata revision date of 2024-03-11 and an Entrez history date of 2024-02-21. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Abaloparatide
DailyMed lists Structured Product Labeling version 16 for the reviewed Abaloparatide label family with a published date of 2024-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Mazdutide
PeptideScanner retained PubMed bibliographic metadata for PMID 38440786 at 2026-07-30T18:48:13.638Z. PubMed recorded a metadata revision date of 2024-03-07 and an Entrez history date of 2024-03-05. PeptideScanner associated this retained record with the identity slug mazdutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02953665 at 2026-07-30T18:47:17.465Z. Its registry update date was 2024-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03672812 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-05, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory · Vosoritide
The Federal Register published notice 2024-04479, attributed to FDA and its parent HHS department, on 2024-03-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; VOXZOGO,” and PeptideScanner's exact reviewed identity mapping connects the document to Vosoritide.
Source: Federal Register via GovInfo ↗
Regulatory · Tirzepatide
The Federal Register published notice 2024-04157, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.
Source: Federal Register via GovInfo ↗
Regulatory · Leuprolide
The Federal Register published notice 2024-04218, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
Source: Federal Register via GovInfo ↗
Clinical trials · Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT04081337 at 2026-07-30T18:48:25.645Z. Its registry update date was 2024-02-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Regulatory · Tesamorelin
DailyMed lists Structured Product Labeling version 5 for the reviewed Tesamorelin label family with a published date of 2024-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Teriparatide
DailyMed lists Structured Product Labeling version 4 for the reviewed Teriparatide label family with a published date of 2024-01-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00099086 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02543255 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT04407234 at 2026-07-30T18:49:14.741Z. Its registry update date was 2024-01-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗